New figures from the World Trade Center Health Program show a sharp jump in certified cancers, a sobering reminder that the health toll of that day is still unfolding.
UCLA researchers grew trillions of tumor-hunting T cells from a few cord-blood stem cells — enough for thousands of doses — and, in mice, controlled cancer without the usual donor-cell complication.
In a six-month trial, people with Type 1 diabetes and obesity who ate only between noon and 8 p.m. saw better glucose control than calorie-cutters — with no rise in dangerous highs or lows.
The accelerated approval lets patients with HER2-mutant non-small cell lung cancer take sevabertinib right away, without needing to try chemotherapy first.
Interim trial data showed up to 79% fewer monthly seizures after a single dose — and now Encoded Therapeutics has fresh funding to drive its Dravet syndrome gene therapy toward pivotal trials.
The new immuno-oncology company is betting a next-generation CTLA-4 antibody with a short half-life can crack “cold” colon tumors that resist today’s immunotherapy.
An intravenous gene therapy extended survival up to threefold and eased symptoms in cats with Sandhoff disease — an early but hopeful step toward treating a disorder that usually kills children by age four.
Studies increasingly tie Helicobacter pylori infection to colorectal cancer, but whether treating the bug lowers that risk remains genuinely unsettled.
At a major lung conference, AstraZeneca reported that its IL-33 inhibitor tozorakimab significantly reduced the airway-clogging mucus plugs that worsen COPD.
ARPA-H’s new ADVOCATE program aims to build the first FDA-authorized “agentic” AI that can autonomously adjust heart-failure care — assessing symptoms, ordering labs, even prescribing.
A 15,000-person Swedish study found people with bipolar disorder taking semaglutide had a 21% lower risk of psychiatric hospitalization — an intriguing signal, but not proof, and not seen with every GLP-1 drug.
Del-desiran, the lead muscle-disease therapy Novartis bought with Avidity for $12 billion, missed its main goal in myotonic dystrophy — sending the stock to its worst day since 2020.